This company has been acquired
DICE Therapeutics Past Earnings Performance
Past criteria checks 0/6
DICE Therapeutics's earnings have been declining at an average annual rate of -51%, while the Pharmaceuticals industry saw earnings growing at 16% annually.
Key information
-51.0%
Earnings growth rate
48.6%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | n/a |
| Return on equity | -20.1% |
| Net Margin | n/a |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
We're Not Very Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Rate
May 14
DICE Therapeutics positive phase 1 data for psoriasis candidate leads shares 71% higher
Oct 11Here's Why We're Not Too Worried About DICE Therapeutics' (NASDAQ:DICE) Cash Burn Situation
Sep 11DICE Therapeutics GAAP EPS of -$0.58
Aug 11DICE Therapeutics initiated at buy at Wainwright on platform for small molecule drugs
Jul 18Revenue & Expenses BreakdownBeta
How DICE Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 0 | -104 | 32 | 24 |
| 31 Mar 23 | 0 | -91 | 28 | 0 |
| 31 Dec 22 | 0 | -84 | 26 | 0 |
| 30 Sep 22 | 0 | -77 | 23 | 0 |
| 30 Jun 22 | 0 | -74 | 21 | 0 |
| 31 Mar 22 | 1 | -59 | 16 | 0 |
| 31 Dec 21 | 1 | -49 | 12 | 0 |
| 30 Sep 21 | 1 | -40 | 9 | 0 |
| 30 Jun 21 | 2 | -29 | 7 | 0 |
| 31 Mar 21 | 1 | -27 | 5 | 0 |
| 31 Dec 20 | 1 | -24 | 5 | 0 |
| 31 Dec 19 | 6 | -13 | 4 | 0 |
Quality Earnings: DICE is currently unprofitable.
Growing Profit Margin: DICE is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: DICE is unprofitable, and losses have increased over the past 5 years at a rate of 51% per year.
Accelerating Growth: Unable to compare DICE's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: DICE is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-16.4%).
Return on Equity
High ROE: DICE has a negative Return on Equity (-20.08%), as it is currently unprofitable.